FrancophonIA/ELRC3.0 huggingface dataset:
English: Uncommon: dyspnoea
Estonian: Sage: somnolentsus
English: There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and topical brinzolamide.
Estonian: Suukaudsete karboanhüdraasi inhibiitorite ja lokaalse brinsolamiidi kasutamisel võib karboanhüdraasi inhibiitorite teadaolev süsteemne toime tugevneda.
English: 2, abdominal discomfort diarrhoea
Estonian: 2, ebamugavustunne kõhus kõhulahtisus
English: Uncommon: pain
Estonian: Teadmata: valu rinnus
English: - If you have any further questions, ask your doctor, optometrist (optician) or pharmacist.
Estonian: - Kui teil on lisaküsimusi, pidage nõu oma arsti, optometristi (silmaarsti) või apteekriga.
English: -8.5 (n=384) -8.3 (n=373)
Estonian: -8,3 (n=373)
English: -8.5 (n=384) -8.4 (n=377)
Estonian: -8,4 (n=377)
English: Brinzolamide is a carbonic anhydrase inhibitor and, although administered topically, is absorbed systemically.
Estonian: Brinsolamiid on karboanhüdraasi inhibiitor, mis ka lokaalse manustamise korral imendub süsteemselt.
English: 1, ocular discomfort
Estonian: 1, ebamugavustunne silmas hägune nägemine
English: If you get any side effects, talk to your doctor, optometrist (optician) or pharmacist.
Estonian: Kui teil tekib ükskõik milline kõrvaltoime, pidage nõu oma arsti, optometristi (optiku) või apteekriga.
English: SIMBRINZA has not been studied in patients with hepatic impairment and caution is therefore recommended in this population (see section 4.4).
Estonian: Kasutamine maksa- ja/või neerukahjustuse korral SIMBRINZAt ei ole uuritud maksakahjustusega patsientidel ning seetõttu on soovitatav nendel patsientidel ravimit kasutada ettevaatusega (vt lõik 4.4).
English: Keep this medicine out of the sight and reach of children.
Estonian: Kuidas SIMBRINZA't säilitada Hoidke seda ravimit laste eest varjatud ja kättesaamatus kohas.
English: Twist off the bottle cap. After the cap is removed, if the tamper evident snap collar is loose, remove it before using the medicine.
Estonian: Pärast korgi eemaldamist eemaldage turvasulgur, kui see on lahti tulnud.
English: , erythema
Estonian: , erüteem
English: Bring the bottle tip close to the eye. Do this in front of a mirror if it helps.
Estonian: Viige pudeli otsik silmale lähemale.
English: Not known: arthralgia
Estonian: Teadmata: astma
English: - If you get any side effects, talk to your doctor, optometrist (optician) or pharmacist.
Estonian: - Kui teil tekib ükskõik milline kõrvaltoime, pidage nõu oma arsti, optometristi (silmaarsti) või apteekriga.
English: No accumulation occurs during chronic administration.
Estonian: Pikaajalise manustamise korral akumulatsiooni ei kaasne.
English: 2, paraesthesia oral
Estonian: 2, epistaksis
English: 1, oesophagitis
Estonian: 1, aevastamine
English: 1, rhinorrhoea
Estonian: 1, pearinglus
English: Propylene glycol
Estonian: Vaimne erksus
English: Uncommon: nasopharyngitis
Estonian: Aeg-ajalt: nasofarüngiit
English: Uncommon: back pain
Estonian: Aeg-ajalt: valu
English: Figure 1 Mean a diurnal (9 AM, +2 hrs, +7 hrs) IOP change from baseline (mmHg)Contribution of elements study aLeast squares means derived from a statistical model that accounts for study site, 9 AM baseline IOP stratum, and correlated IOP measurements within patient.
Estonian: Joonis 1 Keskmise a ööpäevase (09:00, + 2 tundi, + 7 tundi) silmasisese rõhu muutus algväärtusest (mmHg) - toimeainete ühise toime kliiniline uuring Silmasisese rõhu muutus (mmHg) vähimruutude keskmised
English: 1, meibomianitis
Estonian: 1, ösofagiit
English: Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and carcinogenic potential.
Estonian: Brinsolamiidi farmakoloogilise ohutuse, korduvtoksilisuse, genotoksilisuse ja kartsinogeensuse mittekliinilised uuringud ei ole näidanud kahjulikku toimet inimesele.
English: 1, visual acuity reduced
Estonian: 1, nägemishäired
English: SIMBRINZA has not been studied in patients with hepatic impairment; caution should be used in treating such patients (see section 4.2).
Estonian: Seetõttu tuleb ravimit nendel patsientidel kasutada ettevaatusega (vt lõik 4.2).
English: Brinzolamide pharmacokinetics are inherently non-linear due to saturable binding to carbonic anhydrase in whole blood and various tissues.
Estonian: Küllastuva seondumise tõttu karboanhüdraasiga täisveres ja erinevates kudedes on brinsolamiidi farmakokineetika oma olemuselt mittelineaarne.
English: It should be used with caution in dry eye patients and in patients whose cornea may be compromised.
Estonian: Kuivsilmsusega ja kahjustunud sarvkestaga patsientidel tuleb seda ettevaatusega kasutada.
English: 2, angina pectoris
Estonian: 2, sage roojamine
English: 2, scleral pigmentation
Estonian: 2, farüngolarüngeaalne valu
English: 2, upper respiratory tract congestion nasal congestion
Estonian: 2, ülemiste hingamisteede turse
English: 2, sinusitis
Estonian: 2, suu paresteesia
English: 2, myalgia
Estonian: 2, helkimine
English: Not known: face oedema
Estonian: Teadmata: näo turse
English: This summary was last updated in 07-2009.
Estonian: Kokkuvõtte viimane uuendus: 07-2009
English: The European Commission granted a marketing authorisation valid throughout the EU for Zyllt to Krka, d.d., Novo mesto on 28 September 2009.
Estonian: Euroopa Komisjon andis Zyllti müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Krka, d.d., Novo mesto 28. septembril 2009.
English: Zyllt clopidogrel EPAR summary for the public
Estonian: Zyllt klopidogreel Kokkuvõte üldsusele
English: Zyllt can be given to the following groups of patients:
Estonian: Zyllti saab kasutada järgmiste patsiendirühmade korral:
English: The Committee recommended that Zyllt be given marketing authorisation.
Estonian: Komitee soovitas anda Zylltile müügiloa.
English: Zyllt can be started between seven days and six months after the stroke;
Estonian: Zyllti manustamist saab alustada seitsme päeva kuni kuue kuu jooksul pärast insulti;
English: The standard dose of Zyllt is one 75 mg tablet once a day, taken with or without food.
Estonian: Zyllti tavaannus on üks 75 mg tablett üks kord ööpäevas koos toiduga või ilma.
English: In acute coronary syndrome, Zyllt is used together with aspirin and treatment generally starts with a loading dose of four 75 mg tablets.
Estonian: Akuutse koronaarsündroomi korral kasutatakse Zyllti koos aspiriiniga; ravi algab üldiselt küllastusannusega, kus võetakse neli 75 mg tabletti.
English: Zyllt is a ‘generic medicine'.
Estonian: Zyllt on geneeriline ravim.
English: This is then followed by the standard 75 mg dose once a day for at least four weeks (in ST segment elevation myocardial infarction) or for up to 12 months (in non-ST segment elevation syndrome).
Estonian: Seejärel jätkatakse tavalise 75 mg annusega ööpäevas vähemalt neli nädalat (ST-segmendi elevatsiooniga infarkti korral) või kuni 12 kuud (ST-segmendi elevatsiooni puudumise korral).
English: Zyllt can be started between a few days and 35 days after the attack;
Estonian: Zyllti manustamist saab alustada mõne kuni 35 päeva jooksul pärast infarkti;
English: Because Zyllt is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as those of the reference medicine.
Estonian: Et Zyllt on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: What is Zyllt?
Estonian: Mis on Zyllt?
English: What are the benefit and risk of Zyllt?
Estonian: Milles seisneb Zyllti kasulikkus ja mis riskid Zylltiga kaasnevad?
English: The full EPAR for Zyllt can be found here.
Estonian: Euroopa avaliku hindamisaruande täisteksti Zyllti kohta leiate siit.
English: Zyllt is a medicine that contains the active substance clopidogrel.
Estonian: Zyllt on ravim, mis sisaldab toimeainena klopidogreeli.
English: Other information about Zyllt:
Estonian: Muu teave Zyllti kohta
English: This means that Zyllt is similar to a ‘reference medicine' already authorised in the European Union (EU) called Plavix.
Estonian: See tähendab, et Zyllt on sarnane võrdlusravimiga Plavix, millel juba on Euroopa Liidus müügiluba.
English: Therefore, the CHMP's view was that, as for Plavix, the benefit outweighs the identified risk.
Estonian: Seetõttu arvas inimravimite komitee, et nagu ka Plavixi korral, ületab Zyllti kasulikkus sellega kaasnevad riskid.
English: Because Zyllt is a generic medicine, studies have been limited to tests to determine that it is bioequivalent to the reference medicine, Plavix.
Estonian: Et Zyllt on geneeriline ravim, piirdusid uuringud katsetega, milles näidati Zyllti bioekvivalentsust võrdlusravimiga Plavix.
English: The Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Zyllt has been shown to have comparable quality and to be bioequivalent to Plavix.
Estonian: Inimravimite komitee otsustas, et vastavalt Euroopa Liidu nõuetele on tõendatud Zyllti võrdväärne kvaliteet ja bioekvivalentsus ravimiga Plavix.
English: Why has Zyllt been approved?
Estonian: Miks Zyllt heaks kiideti?
English: Zyllt can be used in patients who are having myocardial infarction with ‘ST segment elevation' (an abnormal reading on the electrocardiogram or ECG) when the doctor thinks that they would benefit from the treatment.
Estonian: Zyllti võib manustada ka patsientidele, kellel on STsegmendi elevatsiooniga (elektrokardiogrammi ehk EKG teatud ebanormaalne näit) südameinfarkt, kui arst arvab, et ravimist on patsiendile kasu.
English: Clopidogrel stops the platelets aggregating by blocking a substance called ADP from attaching to a special receptor on their surface.
Estonian: Klopidogreel peatab vereliistakuteagregatsiooni, tõkestades adenosiindifosfaadi seondumist teatud retseptoriga liistakute pinnal.
English: Zyllt is used in adults to prevent atherothrombotic events (problems caused by blood clots and hardening of the arteries).
Estonian: Zyllti kasutatakse aterotrombootiliste nähtude (trombide ehk soonesiseste verehüüvete moodustumisest ja arterite lubjastumisest põhjustatud probleemide) ennetamiseks täiskasvanutel.
English: When the blood clots, this is due to special cells in the blood called platelets aggregating (sticking together).
Estonian: Veri hüübib teatud vererakkude vereliistakute - agregatsiooni (kokkukleepumise) tõttu.
English: How is Zyllt used?
Estonian: Kuidas Zyllti kasutatakse?
English: How does Zyllt work?
Estonian: Kuidas Zyllt toimib?
English: What is Zyllt used for?
Estonian: Milleks Zyllti kasutatakse?
English: How has Zyllt been studied?
Estonian: Kuidas Zyllti uuriti?
English: The active substance in Zyllt, clopidogrel, is an inhibitor of platelet aggregation.
Estonian: Zyllti toimeaine klopidogreel on trombotsüütide agregatsiooni (vereliistakute kokkukleepumise) inhibiitor, mis aitab ennetada organismis trombide tekkimist.
English: • patients who have a condition known as ‘acute coronary syndrome', when it should be given with aspirin (another medicine that prevents blood clots), including patients who have had a stent inserted (a short tube placed in an artery to prevent it closing up).
Estonian: Sel juhul tuleb Zyllti manustada koos aspiriiniga (samuti antikoagulant), sealhulgas patsientidele, kellele on paigaldatud stent (ahenenud arterit avardav väike toru).
English: The full EPAR for Actelsar HCT can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Actelsar HCT kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: What measures are being taken to ensure the safe and effective use of Actelsar HCT?
Estonian: Mis meetmeid võetakse, et tagada Actelsar HCT ohutu ja efektiivne kasutamine?
English: The European Commission granted a marketing authorisation valid throughout the European Union for Actelsar HCT on 13 March 2013.
Estonian: Euroopa Komisjon andis Actelsar HCT müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 13. märtsil 2013.
English: It is used in adults who have essential hypertension (high blood pressure) that is not adequately controlled by telmisartan alone.
Estonian: Seda kasutatakse essentsiaalse hüpertensiooniga (kõrgvererõhutõvega) patsientidel, kelle vererõhku ei saa ainult telmisartaaniga piisavalt reguleerida.
English: The Committee recommended that Actelsar HCT be approved for use in the EU.
Estonian: Komitee soovitas Actelsar HCT kasutamise Euroopa Liidus heaks kiita.
English: The 80/25 mg tablets are used in patients whose blood pressure is not controlled using the 80/12.5 mg tablets or who have been stabilised using the two active substances taken separately before switching to Actelsar HCT.
Estonian: 80/25 mg tablette kasutatakse patsientidel, kelle vererõhk ei allu ravile 80/12,5 mg tablettidega või kelle vererõhk on enne Actelsar HCT-le üleminekut kahe toimeaine eraldi manustamise abil stabiliseerunud.
English: telmisartan / hydrochlorothiazide
Estonian: telmisartaan / hüdroklorotiasiid
English: Actelsar HCT is available as tablets (40 mg or 80 mg telmisartan and 12.5 mg hydrochlorothiazide; 80 mg telmisartan and 25 mg hydrochlorothiazide) to be taken by mouth once a day with liquid.
Estonian: Actelsar HCT-d turustatakse suukaudsete tablettidena (40 mg või 80 mg telmisartaani ja 12,5 mg hüdroklorotiasiidi; 80 mg telmisartaani ja 25 mg hüdroklorotiasiidi), mida võetakse koos vedelikuga üks kord ööpäevas.
English: This is a summary of the European public assessment report (EPAR) for Actelsar HCT.
Estonian: See on ravimi Actelsar HCT Euroopa avaliku hindamisaruande kokkuvõte.
English: Safety information has been included in the summary of product characteristics and the package leaflet for Actelsar HCT, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Ravimi omaduste kokkuvõttesse ja pakendi infolehele lisati Actelsar HCT ohutusteave koos vastavate ettevaatusabinõudega tervishoiuspetsialistidele ja patsientidele.
English: Therefore, the CHMP's view was that, as for MicardisPlus, the benefit outweighs the identified risk.
Estonian: Seetõttu arvas inimravimite komitee, et nagu ka MicardisPlusi korral, ületab Actelsar HCT kasulikkus sellega kaasnevad riskid.
English: Because Actelsar HCT is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Actelsar HCT on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: The dose of Actelsar HCT to be used depends on the dose of telmisartan that the patient was taking before: patients who were receiving 40 mg telmisartan should take the 40/12.5 mg tablets, and patients who were receiving 80 mg telmisartan should take the 80/12.5 mg tablets.
Estonian: Actelsar HCT annus sõltub patsiendi varasemast telmisartaani annusest: 40/12,5 mg tablette võib anda patsientidele, kes said varem 40 mg telmisartaani, ja 80/12,5 mg tablette patsientidele, kes said varem 80 mg telmisartaani.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Actelsar HCT has been shown to have comparable quality and to be bioequivalent to MicardisPlus.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud Actelsar HCT võrdväärne kvaliteet ja bioekvivalentsus ravimiga MicardisPlus.
English: Why is Actelsar HCT approved?
Estonian: Miks Actelsar HCT heaks kiideti?
English: What is Actelsar HCT and what is it used for?
Estonian: Mis on Actelsar HCT ja milleks seda kasutatakse?
English: Other information about Actelsar HCT
Estonian: Muu teave Actelsar HCT kohta
English: This means that Actelsar HCT is similar to a ‘reference medicine' already authorised in the European Union (EU) called MicardisPlus.
Estonian: See tähendab, et Actelsar HCT on sarnane võrdlusravimiga MicardisPlus, millel juba on Euroopa Liidus müügiluba.
English: Actelsar HCT is a medicine that contains two active substances, telmisartan and hydrochlorothiazide.
Estonian: Actelsar HCT on ravim, mis sisaldab kaht toimeainet: telmisartaani ja hüdroklorotiasiidi.
English: It is not intended to provide practical advice on how to use Actelsar HCT.
Estonian: Hindamisaruandes ei anta Actelsar HCT kasutamise praktilisi nõuandeid.
English: Actelsar HCT is a ‘generic medicine'.
Estonian: Actelsar HCT on geneeriline ravim.
English: Because Actelsar HCT is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, MicardisPlus.
Estonian: Et Actelsar HCT on geneeriline ravim, piirdusid uuringud katsetega, milles näidati selle bioekvivalentsust võrdlusravimiga MicardisPlus.
English: For practical information about using Actelsar HCT, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Actelsar HCT kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: Actelsar HCT contains two active substances, telmisartan and hydrochlorothiazide.
Estonian: Actelsar HCT sisaldab kaht toimeainet: telmisartaani ja hüdroklorotiasiidi.
English: For more information about treatment with Actelsar HCT, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Actelsar HCT-ga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: How has Actelsar HCT been studied?
Estonian: Kuidas Actelsar HCT-d uuriti?
English: What are the benefits and risks of Actelsar HCT?
Estonian: Milles seisneb Actelsar HCT kasulikkus ja mis riskid ravimiga kaasnevad?
English: How does Actelsar HCT work?
Estonian: Kuidas Actelsar HCT toimib?
English: How is Actelsar HCT used?
Estonian: Kuidas Actelsar HCT-d kasutatakse?
English: What measures are being taken to ensure the safe and effective use of Humira?
Estonian: Mis meetmed võetakse, et tagada Humira ohutu ja efektiivne kasutamine?
English: Humira received a marketing authorisation valid throughout the EU on 8 September 2003.
Estonian: Humira on saanud müügiloa, mis kehtib kogu ELis, 8. septembril 2003.
English: Below is a brief description of the studies and their results:
Estonian: Järgnevalt on toodud uuringute lühikirjeldus ja tulemused.
English: Further information on Humira can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/humira.
Estonian: Lisateave Humira kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/humira.
English: Humira (adalimumab)
Estonian: Humira (adalimumaab)
English: What is Humira and what is it used for?
Estonian: Mis on Humira ja milleks seda kasutatakse?
English: Some rare but serious side effects have been reported, including serious infections.
Estonian: Teatatud on harvaesinevatest, kuid rasketest kõrvalnähtudest, sealhulgas rasketest infektsioonidest.
English: However, these are considered to be manageable and specific recommendations are given to help doctors manage these risks.
Estonian: Neid peetakse aga hallatavateks ja arstidele antakse konkreetsed soovitused riskide vähendamiseks.
English: As for all medicines, data on the use of Humira are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Humira kasutamise kohta pidevat järelvalvet.
English: The European Medicines Agency decided that Humira's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Humira kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: How is Humira used?
Estonian: Kuidas Humirat kasutatakse?
English: Humira is given as an injection under the skin, usually every 2 weeks.
Estonian: Humirat manustatakse nahaaluse süstina tavaliselt iga kahe nädala järel.
English: Patients or their carers can inject Humira once they have been trained.
Estonian: Patsiendid (või nende hooldajad) tohivad Humirat ise süstida, kui nad on saanud asjakohase väljaõppe.
English: What are the risks associated with Humira?
Estonian: Mis riskid Humiraga kaasnevad?
English: Other information about Humira
Estonian: Muu teave Humira kohta
English: Humira is a medicine that acts on the immune system and is used to treat the following conditions:
Estonian: Humira on immuunsüsteemi ravim ja seda kasutatakse järgmiste haiguste korral:
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Humira have also been included in the summary of product characteristics and the package leaflet.
Estonian: Humira ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Humira is mostly used in adults when their conditions are severe, moderately severe or getting worse, or when patients cannot use other treatments.
Estonian: Humirat kasutatakse enamasti raskes, mõõdukalt raskes või halvenevas seisundis täiskasvanutel või kui patsiendid ei saa muid ravimeid kasutada.
English: How does Humira work?
Estonian: Kuidas Humira toimib?
English: The study in younger children (aged 2 to 4 years) showed that the majority of children responded well to Humira treatment and this response was maintained after 24 weeks.
Estonian: 2-4-aastaste väikelaste uuring näitas, et lastest enamikul tekkis Humirale soodne ravivastus, mis säilis pärast 24 nädalat.
English: The proportions of patients taking placebo who achieved this goal were 28% in the first study and 26% in the second.
Estonian: Platseeboga olid samad näitajad esimeses uuringus 28% ja teises uuringus 26%.
English: Side effects reported with Humira are carefully evaluated and any necessary action taken to protect patients.
Estonian: Humira kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: The first study involved adults whose disease was not controlled with high doses of corticosteroids.
Estonian: Esimeses uuringus osalesid täiskasvanud patsiendid, kelle haigus ei allunud ravile kortikosteroidide suurte annustega.
English: Patients adding Humira also had less joint damage and less reduction in physical function after a year.
Estonian: Humirat kasutanud patsientidel oli ka vähem liigesekahjustusi ja nende füüsiline aktiivsus vähenes pärast aastast ravi vähem.
English: • In non-infectious uveitis, Humira was found effective in 3 studies.
Estonian: • Mittenakkusliku uveiidi ravis osutus Humira efektiivseks kolmes uuringus.
English: Patients treated with Humira must be given a reminder card with information on the safety of the medicine.
Estonian: Humiraga ravitavatele patsientidele tuleb anda hoiatuskaart, millel on ravimi ohutusteave.
English: In patients who had not taken methotrexate in the past, the combination of Humira and methotrexate was also more effective than methotrexate alone.
Estonian: Patsientidel, kes ei olnud varem kasutanud metotreksaati, oli Humira ja metotreksaadi koos kasutamine samuti efektiivsem kui metotreksaadi kasutamine ainsa ravimina.
English: The active substance in Humira, adalimumab, is a monoclonal antibody (a type of protein) that has been designed to recognise and attach to a substance in the body called tumour necrosis factor (TNF).
Estonian: Humira toimeaine adalimumaab on monoklonaalne antikeha (teatud valk), mis tunneb ära organismis leiduva aine kasvaja nekroositeguri (TNF) ja seondub sellega.
English: Humira and other medicines of its class may also affect the ability of the immune system to fight off infections and cancer, and there have been some cases of serious infections and blood cancers in patients using Humira.
Estonian: Humira ja teised sama klassi ravimid võivad mõjutada ka immuunsüsteemi võimet võidelda infekstioonide ja vähiga (Humirat kasutanud patsientidel on olnud raske infektsiooni või verevähi juhtumeid).